Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly EBT Margin came in at 7987.76% in Q2 2026, down 527601.0% YoY from N/an in Q2 2025, and down 16.81% on a QoQ basis from 6837.99% in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of EBT Margin data on file, last reported at 7987.76% in Q2 2026.
- Quarterly EBT Margin fell 527601.0% year-over-year to 7987.76% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 319.14% (up 99835.0% YoY) and the FY2025 annual result came in at 310.61%, up 19857.0% from the prior year.
- EBT Margin declined to 7987.76% in Q2 2026, from 6837.99% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 53.25% in Q4 2025 to a low of 7987.76% in Q2 2026.
- A 5-year average of 1580.42% and a median of 767.72% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin soared 153116 bps — and 2026, when it plunged 621816 bps.
- Tracing BCYC's EBT Margin over 5 years: stood at 386.1% in 2022, then plunged by 155 bps to 985.78% in 2023, then plunged by 61 bps to 1584.41% in 2024, then soared by 97 bps to 53.25% in 2025, then tumbled by 14900 bps to 7987.76% in 2026.
- The last three EBT Margin figures came in at 7987.76% (Q2 2026), 6837.99% (Q1 2026), and 53.25% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -7,987.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,987.76% |
| Mar 31, 2026 | -6,837.99% |
| Dec 31, 2025 | -53.25% |
| Sep 30, 2025 | -501.92% |
| Jun 30, 2025 | -2,711.75% |
| Mar 31, 2025 | -619.84% |
| Dec 31, 2024 | -1,584.41% |
| Sep 30, 2024 | -2,027.28% |
| Jun 30, 2024 | -424.07% |
| Mar 31, 2024 | -137.80% |
| Dec 31, 2023 | -985.78% |
| Sep 30, 2023 | -889.87% |
| Jun 30, 2023 | -378.35% |
| Mar 31, 2023 | -810.50% |
| Dec 31, 2022 | -386.10% |
| Sep 30, 2022 | -940.30% |
| Jun 30, 2022 | -324.70% |
| Mar 31, 2022 | -724.95% |
| Dec 31, 2021 | -1,240.56% |
| Sep 30, 2021 | -348.33% |